Controlled Human Malaria Infection Transmission Model

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

SUSPENDED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

44 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-08-22

Study Completion Date

2026-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is to develop a model to test the efficacy of vaccines and/or drugs designed to block transmission of malaria to mosquitoes and to identify the targets of transmission-blocking immunity to malaria.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Controlled Human Malaria Infection Model for Evaluation of Transmission-Blocking Interventions - Study 1

NCT02836002

Malaria

COMPLETED PHASE1/PHASE2

Controlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2

NCT03454048

Malaria,Falciparum Gametocytes Controlled Human Malaria Infection +1 more

COMPLETED NA

A Study of Blood-stage Controlled Human Plasmodium Falciparum Malaria Infection in Tanzania

NCT04788862

Malaria Plasmodium Falciparum

COMPLETED NA

Safe and Efficacious Artemisinin-based Combination Treatments for African Pregnant Women With Malaria

NCT00852423

Malaria in Pregnancy

COMPLETED PHASE3

Malaria as a Risk Factor for COVID-19 in Western Kenya and Burkina Faso

NCT04695197

Covid-19 Malaria

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Malaria is a disease of major public health importance. The only vaccine available is partially effective and targets the pre-erythrocytic stages of the life cycle. Thus, there is a need to identify other potential vaccine targets as well as to develop models to test vaccine efficacy, especially that of transmission-blocking vaccines. Controlled human malaria infection (CHMI) has been shown to be an important tool for the assessment of the efficacy of novel malaria vaccines and drugs. CHMI also allows for the evaluation of immunity to malaria and monitoring of parasite growth rates in vivo. This is particularly useful in individuals from endemic areas with varying levels of exposure and immunity to malaria. Thus, CHMI in individuals with prior exposure to malaria has potential to accelerate malaria vaccine development. In this study, the aim is to use CHMI in semi-immune adults to develop a model to assess transmissibility of malaria infection to mosquitoes, to study immune responses that are directed against sexual stages that might block transmission, and as a platform to test vaccines. To achieve this, the study will be carried out in two phases A (N=45 participants) and B (N=60 participants) over a period of 4-6months. Parasite dose will be varied in individuals enrolled for CHMI and use of low-doses of anti-malarial drugs to promote the production of gametocytes in vivo (Phase A) and demonstrate transmissibility in mosquito feeding assays (Phase B). Thus, the main outcomes of the study will be: (1) optimisation of sporozoite dose for infections success in individuals with moderate-high malaria exposure; (2) use of sub-curative anti-malaria treatment for induction of gametocytes; and (3) infection of mosquitoes in mosquito feeding assays by induced gametocytes. To achieve this, up to 250 semi-immune adults will be recruited from known areas of malaria endemicity in Kenya with varying exposure to malaria undergo screening procedures after informed consent to enrol 105 individuals to conduct CHMI studies with serial quantitative polymerase chain reaction (PCR) to measure asexual parasite growth and induction of transmission stages in vivo. In addition, comprehensively characterize immunity and identify targets in relation to function assessed by various laboratory assays.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malaria,Falciparum

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1: PfSPZ 6,400

Group 1 will receive a malaria infection by direct venous inoculation (DVI) with PfSPZ Challenge at a dose of 6,400 sporozoites.

Group 1 will be randomised (1:1) to receive either sub-curative Sulfadoxine-Pyrimethamine (SP) (500mg/25mg) or Piperaquine (PIP) (480mg).

Group 1 will receive a final curative treatment of Artemether-Lumefantrine (AL) with single low dose Primaquine (SLDPQ)

Group Type EXPERIMENTAL

PfSPZ Challenge

Intervention Type BIOLOGICAL

Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites

Sulfadoxine-Pyrimethamine

Intervention Type DRUG

Sub-curative 500mg/25mg single dose regimen

Piperaquine

Intervention Type DRUG

Sub-curative 480mg single dose regimen

Artemether lumefantrine

Intervention Type DRUG

Three day curative regimen 20mg/120mg

Primaquine

Intervention Type DRUG

Single low dose regimen 0.25 mg base/kg

Group 1: PfSPZ 12,800

Group 2 will receive a malaria infection by direct venous inoculation (DVI) with PfSPZ Challenge at a dose of 12,800 sporozoites

Group 2 will be randomised (1:1) to receive either sub-curative Sulfadoxine-Pyrimethamine (SP) (500mg/25mg) or Piperaquine (PIP) (480mg).

Group 2 will receive a final curative treatment of Artemether-Lumefantrine (AL) with single low dose Primaquine (SLDPQ)

Group Type EXPERIMENTAL

PfSPZ Challenge

Intervention Type BIOLOGICAL

Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites

Sulfadoxine-Pyrimethamine

Intervention Type DRUG

Sub-curative 500mg/25mg single dose regimen

Piperaquine

Intervention Type DRUG

Sub-curative 480mg single dose regimen

Artemether lumefantrine

Intervention Type DRUG

Three day curative regimen 20mg/120mg

Primaquine

Intervention Type DRUG

Single low dose regimen 0.25 mg base/kg

Group 3: PfSPZ 25,600

Group 3 will receive a malaria infection by direct venous inoculation (DVI) with PfSPZ Challenge at a dose of 25,600 sporozoites

Group 3 will be randomised (1:1) to receive either sub-curative Sulfadoxine-Pyrimethamine (SP) (500mg/25mg) or Piperaquine (PIP) (480mg).

Group 3 will receive a final curative treatment of Artemether-Lumefantrine (AL) with single low dose Primaquine (SLDPQ)

Group Type EXPERIMENTAL

PfSPZ Challenge

Intervention Type BIOLOGICAL

Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites

Sulfadoxine-Pyrimethamine

Intervention Type DRUG

Sub-curative 500mg/25mg single dose regimen

Piperaquine

Intervention Type DRUG

Sub-curative 480mg single dose regimen

Artemether lumefantrine

Intervention Type DRUG

Three day curative regimen 20mg/120mg

Primaquine

Intervention Type DRUG

Single low dose regimen 0.25 mg base/kg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PfSPZ Challenge

Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites

Intervention Type BIOLOGICAL

Sulfadoxine-Pyrimethamine

Sub-curative 500mg/25mg single dose regimen

Intervention Type DRUG

Piperaquine

Sub-curative 480mg single dose regimen

Intervention Type DRUG

Artemether lumefantrine

Three day curative regimen 20mg/120mg

Intervention Type DRUG

Primaquine

Single low dose regimen 0.25 mg base/kg

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

NF54 Plasmodium falciparum malaria challenge Fansidar Piperaquine Phosphate Coartem

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy adults aged 18 to 45 years.
2. Able and willing (in the Investigator's opinion) to comply with all study requirements.
3. Informed consent.
4. Use of effective method of contraception for duration of study (women only). We will ask the female volunteers to come with their family planning records to verify. Effective contraception is defined as a contraceptive method with failure rate of less than 1% per year when used consistently and correctly, in accordance with the product label. Examples of these include: combined oral contraceptives; injectable progestogen; implants of etenogestrel or levonorgestrel; intrauterine device or intrauterine system; male partner sterilisation at least 6 months prior to the female subject's entry into the study, and the relationship is monogamous; male condom combined with a vaginal spermicide (foam, gel, film, cream or suppository); and male condom combined with a female diaphragm, either with or without a vaginal spermicide (foam, gel, film, cream, or suppository).

Exclusion Criteria

1. Body weight of less than 50kg or body mass index (BMI) less than 18 or greater than 25 kg/m2 at screening.
2. Use of systemic antibiotics with known antimalarial activity within 30 days of administration of PfSPZ Challenge (e.g. trimethoprim-sulfamethoxazole, doxycycline, tetracycline, clindamycin, erythromycin, fluoroquinolones and azithromycin).
3. Receipt of an investigational product in the 30 days preceding enrolment, or planned receipt during the study period.
4. Current participation in another clinical trial or recent participation within 12 weeks of enrolment.
5. Prior receipt of an investigational malaria vaccine.
6. Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed). This will also include Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) positivity.
7. Use of immunoglobulins or blood products within 3 months prior to enrolment.
8. Any serious medical condition reported or identified during screening that increases the risk of CHMI.
9. Any clinically significant abnormal finding on biochemistry or haematology blood tests, urinalysis or clinical examination.
10. Women only; pregnancy, or an intention to become pregnant during the duration of the study.
11. Sickle cell trait or disease.
12. History of drug or alcohol abuse.
13. Known hypersensitivity to or contraindications for use of artemether-lumefantrine, chloroquine, piperaquine, primaquine, sulfadoxine-pyrimethamine, or history of severe (allergic) reactions to mosquito bites.
14. Confirmed gametocyte positivity at screening and/or a day before challenge
15. Confirmed parasite positive by PCR a day before challenge i.e. at C-1. Exclusion Criterion on Day of Challenge

* Acute disease, defined as moderate or severe illness with or without fever (temperature \>37.5 degrees Celcius).

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes